By F. Marcus. Sonoma State University.
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www generic super p-force 160mg on-line most effective erectile dysfunction pills. See Viral hepatitis services applications of data from 160 mg super p-force fast delivery erectile dysfunction causes cycling, 41 cheap super p-force 160mg free shipping varicocele causes erectile dysfunction, 42 cheap 160mg super p-force erectile dysfunction - 5 natural remedies, 43-46 Sexual exposure to hepatitis, 1, 23, 44, 72, at-risk populations, 2, 4, 6, 7, 32, 61-62, 84, 113, 119-120 67, 68, 71-72 Copyright © National Academy of Sciences. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Request reprint permission for this book Copyright © National Academy of Sciences. The members of the Committee responsible for the report were chosen for their special competences and with regard for appropriate balance. N01-0D-4-2139 between the National Academy of Sciences and the National Institutes of Health. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards of objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We thank the following individuals for their review of this report: x Leslie Biesecker, National Institutes of Health x Martin J. Blaser, New York University Langone Medical Center x Wylie Burke, University of Washington x Christopher G. Chute, University of Minnesota and Mayo Clinic x Sean Eddy, Howard Hughes Medical Institute Janelia Farm Research x Elaine Jaffe, National Cancer Institute x Brian J. Schwartz, University of Washington Although the reviewers listed above have provided many constructive comments and suggestions, they were not asked to endorse the conclusions or recommendations, nor did they see the final draft of the report before its release. The review of the report was overseen by Dennis Ausiello, Harvard Medical School, Massachusetts General Hospital and Partners Healthcare and Queta Bond, Burroughs Welcome Fund. Appointed by the National Research Council, they were responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of the report rests entirely with the authoring committee and the institution. We are grateful to those who attended and participated in the workshop “Toward a New st nd Taxonomy of Disease,” held March 1 and 2 , 2011 (Appendix D) and those who discussed data sharing with the Committee during the course of this study. Kelly, Head of Informatics and Strategic Alignment, Aetna x Debra Lappin, President, Council for American Medical Innovation x Jason Lieb, Professor, Department of Biology, University of North Carolina at Chapel Hill x Klaus Lindpaintner, Vice President of R&D, Strategic Diagnostics Inc. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Summary The Committee’s charge was to explore the feasibility and need for “a New Taxonomy of human disease based on molecular biology” and to develop a potential framework for creating one. Clearly, the motivation for this study is the explosion of molecular data on humans, particularly those associated with individual patients, and the sense that there are large, as-yet- untapped opportunities to use these data to improve health outcomes. The Committee agreed with this perspective and, indeed, came to see the challenge of developing a New Taxonomy of Disease as just one element, albeit an important one, in a truly historic set of health-related challenges and opportunities associated with the rise of data-intensive biology and rapidly expanding knowledge of the mechanisms of fundamental biological processes. Hence, many of the implications of the Committee’s findings and recommendations ramify far beyond the science of disease classification and have substantial implications for nearly all stakeholders in the vast enterprise of biomedical research and patient care. Given the scope of the Committee’s deliberations, it is appropriate to start this report by tracing the logical thread that unifies the Committee’s major findings and recommendations and connects them to its statement of task. The Committee’s charge highlights the importance of taxonomy in medicine and the potential opportunities to use molecular data to improve disease taxonomy and, thereby, health outcomes. Taxonomy is the practice and science of classification, typically considered in the context of biology (e. The Committee envisions these data repositories as essential infrastructure, necessary both for creating the New Taxonomy and, more broadly, for integrating basic biological knowledge with medical histories and health outcomes of individual patients. The Committee believes that building this infrastructure—the Information Commons and Knowledge Network—is a grand challenge that, if met, would both modernize the ways in which biomedical research is conducted and, over time, lead to dramatically improved patient care (see Figure S-1). Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease ʹ Figure S-1: Creation of a New Taxonomy first requires an “Information Commons” in which data on large populations of patients become broadly available for research use and a “Knowledge Network” that adds value to these data by highlighting their interconnectedness and integrating them with evolving knowledge of fundamental biological processes. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease ͵ The Committee envisions this ambitious program, which would play out on a time scale of decades rather than years, as proceeding through a blend of top-down and bottom-up activity. A major top-down component, initiated by public and private agencies that fund and regulate biomedical research, would be required to insure that results of individual projects could be combined to create a broadly useful and accessible Information Commons and to establish guidelines for handling the innumerable social, ethical, and legal issues that will arise as data on individual patients become widely shared research resources. However, as is appropriate for a framework study, the Committee did not attempt to design the Information Commons, the Knowledge Network, or the New Taxonomy itself and would discourage funding agencies from over-specifying these entities in advance of initial efforts to create them. What is needed, in the Committee’s view, is a creative period of bottom-up research activity, organized through pilot projects of increasing scope and scale, from which the Committee is confident best practices would emerge. Particularly given the size and diversity of the health-care enterprise, no one approach to gathering the data that will populate the Information Commons is likely to be appropriate for all contributors. As in any initiative of this complexity, what will be needed is the right level of coordination and encouragement of the many players who will need to cooperate to create the Information Commons and Knowledge Network and thereby develop a New Taxonomy. If coordination is too rigid, much-needed innovation and adaptation to local circumstances will be stifled, while if it is too lax, it will be impossible to integrate the data that are gathered into a whole whose value greatly exceeds that of the sum of its parts, an objective the Committee believes is achievable with effective central leadership. Conclusions The Committee hosted a two day workshop that convened diverse experts in both basic and clinical disease biology to address the feasibility, need, scope, impact, and consequences of creating a “New Taxonomy of human diseases based on molecular biology”. The information and opinions conveyed at the workshop informed and influenced an intensive series of Committee deliberations (in person and by teleconference) over a 6 month period, which led to the following conclusions: 1. Because new information and concepts from biomedical research cannot be optimally incorporated into the disease taxonomy of today, opportunities to define diseases more precisely and to inform health care decisions are being missed. Many disease subtypes with distinct molecular causes are still classified as one disease and, conversely, multiple different diseases share a common molecular cause. The failure to incorporate optimally new biological insights results in delayed adoption of new practice guidelines and wasteful health care expenditures for treatments that are only effective in specific subgroups. Dramatic advances in molecular biology have enabled rapid, comprehensive and cost efficient analysis of clinical samples, resulting in an explosion of disease-relevant data with the potential to dramatically alter disease classification. Fundamental discovery research is defining at the molecular level the processes that define and drive physiology. These developments, coupled with parallel advances in information technologies and electronic medical records, provide a transformative opportunity to create a new system to classify disease.
For some consumers buy generic super p-force 160 mg erectile dysfunction at age 27, the convenience outweighed 132 Digital Medicine the loss of choice involved purchase super p-force 160mg visa erectile dysfunction meds at gnc. For many others discount 160 mg super p-force with visa erectile dysfunction groups in mi, the interference with established relationships with hospitals and doctors represented an intolerable intrusion by the health plan into their lives buy super p-force 160mg low cost erectile dysfunction 42. The Internet has given employers and health plans a powerful tool that enables the “mass customization” of networks to accommodate consumers’ existing relationships with doctors and hospitals. Indeed, some employers are going further by simply outsourc- ing choice of health plans and providers through what is called “deﬁned contribution” health beneﬁts. This approach is modeled on the 401(k) pension beneﬁt, in which the employer funds the beneﬁt, but the employee manages it, selecting the mutual fund or investments that best meet their ﬁnancial objectives and needs. Under a deﬁned-contribution health beneﬁt, employers fund the beneﬁt, but employees target it. Using a personal web page, employers can give their employees a vehicle for placing themselves in a health plan, or, using a somewhat more radical approach, employees can select their own provider network (primary care physician, specialists, hospitals, pharmacies, etc. A recently launched Internet health enterprise, Vivius, is help- ing employers and health plans bring this capability to employees. Working with health plans, Vivius provides employees a personal web page that enables them to select their own physicians based on their stated rates. Rather, providers set their own per capita payment rate for individ- ual consumer (that is, a monthly rate per consumer). This rate is adjusted automatically by Vivius software to reﬂect the age and sex of the patient. After selecting the doctors and hospitals they wish to work with, Vivius adds the total cost of contracting with these physicians and compares it to the amount that the employer has contributed. The total amount the consumer pays in a year is capped, and a wrap-around Health Plans 133 indemnity insurance product, protecting the consumer from catas- trophic medical expenses, funds costs above the cap. There are a number of companies in this “virtual” health plan market, with variations on this model, including Deﬁnity, Luminos, and Health- Market. If the claims trail becomes digital, it is possible for consumers to type in a security code and password and track the status of their medical claims. This is essentially the same process that Federal Express uses to enable consumers to track packages on the FedEx web site. Consumers’ personal health beneﬁts web pages can be cus- tomized to help them select their own unique coverage and enable consumers to ﬁnd out quickly if a service is covered and how much their share of the cost will be. It can also enable consumers to read the criteria the managed care plan used to decide if a service is covered and the process by which the plan arrived at its policy. Finally, the personal web site can be customized to deliver health information on issues particularly relevant to the consumer. A common denominator of all of these consumer service op- portunities for health plans is that, to some degree, they all in- volve “outsourcing” to the customer various functions formerly performed by the plan. The list of beneﬁts from this practice is not insigniﬁcant: reducing medical risk; more efﬁciently ﬁghting chronic disease; making better decisions about what care is needed; choosing doctors, hospitals, or beneﬁt designs that meet the con- sumer’s speciﬁc needs; absorbing some of the health plan’s insurance risk (through deﬁned-contribution care); and interacting with the health plan’s administrative systems. Under a deﬁned-contribution model, the employer no longer pro- vides a health beneﬁt, but merely provides employees a ﬁxed amount of money to purchase health coverage. The employee-beneﬁts prece- dent was set by 401(k) plans, which employers fund but employees manage. Deﬁned-contribution healthcare would certainly reinforce a powerful trend toward more consumer inﬂuence over healthcare. Removing the employer from the health plan selection decision also would help to clarify, once and for all, that the real customer of the health plan is the subscriber or family. How practical is it to believe that it will replace conventional deﬁned-beneﬁt health insurance? Realistically, there are numerous practical barriers to its emergence as an alternative to traditional health insurance. These include employer and labor union resis- tance to abandoning deﬁned-beneﬁt coverage, affordability and cost discipline, risk selection, and provider resistance to assuming economic risk. It is also reasonable to assume that consumers will not voluntarily take on additional health cost exposure if they can avoid it. In my view, premature obituaries have been written for the deﬁned-beneﬁt approach to health coverage. While there is some ev- idence of movement by smaller employers to deﬁned-contribution health beneﬁts, the practical barriers to broader adoption are sober- ing. This could increase the cost to employees of achieving the same package of ben- eﬁts by as much as 30 to 40 percent. That is the typical difference between the premiums offered to large groups and those offered to individuals, without the large group’s clout and purchasing power. If all the employer does is give employees a lump sum salary increase equal to what they were previously spending on health insurance premiums, employees get a most unwelcome increase in their taxable income. Employers could continue deducting the amount as a salary expense, but the beneﬁt would no longer be tax free, as health beneﬁts are, to employees. This would take an additional 20 to 40 percent bite out of the health beneﬁts apple. Between the loss of group rates and the taxation, a very signiﬁcant fraction of the economic value of the health beneﬁt to the employee disappears. Employers that incorporate deﬁned-contribution health coverage into a “cafeteria style” beneﬁts plan can take advantage of an existing federal law facilitating movement of beneﬁt dollars between types of beneﬁt (health insurance, vacation, retirement, etc. The federal tax law could be further amended to provide that deﬁned contributions by the employer for health coverage outside of a cafeteria plan could remain tax free to employees. Mechanisms can also be found to pool the purchasing power of employees so that they would not have to enter the health insurance market individually through buyer’s clubs or multiple- employer purchasing pools. Indeed, Internet-based health insurance purchasing exchanges, employing the technologies discussed above, could play a crucial role in preserving employee purchasing power in health insurance markets. Congressional advocates have referred to these pooling mechanisms as “health marts. Healthcare use will change as this happens, but whether these savings will be enough to offset potentially large cost increases borne by the employee remains to be seen. Private health insurers have been systematically stripped of the tools they have used in the past to con- trol medical costs. Those tools included demanding discounts from providers in exchange for (allegedly) bringing them new business, excluding or restricting access to specialists, externally reviewing and challenging the medical necessity of procedures, and simply clogging the claims payment pipeline with bureaucratic processes. Private health insurance premiums have resumed rising at double-digit rates as of this writing, after almost a decade of relative calm. Simply increasing prices, as health plans tend to do when they are in economic trouble, may provide them a short-term in- fusion of cash. But rate increases do nothing to justify the health plan’s removal of between 10 and 20 percent of the premium before actually paying the hospital and doctors. For better or worse, private health plans remain responsible to employers for containing health costs. To paraphrase Jefferson’s comment about the United States and slavery at the turn of the nineteenth century, private health insurers “have the wolf by the ears. The most important emerging leverage point is likely to be the consumer’s household budget. It makes powerful intuitive sense that individuals will spend their own money more carefully than Health Plans 137 they will spend the employer’s money. It is clear that without a greater economic stake in conservative health use by consumers, health costs will not come under control. Notably, it fell even during the period of the managed care revolution (the 1980s and 1990s), because employers used reduced cost sharing as a way of encouraging people to enroll in health plans. Another way of viewing this is that economic risk steadily shifted toward the employer and private health insurance during the man- aged care explosion, and away from consumers. Moreover, the struc- ture of that cost sharing—a nominal copayment of the insurance premium, variable amounts of “ﬁrst dollar” deductibles for various forms of healthcare use (focused primarily on the hospitalization), and a maximum annual cap on the consumer’s cost exposure—had not changed materially in 30 years. Health plans are already experimenting with the use of economic incentives as a way of encouraging consumers to use less expensive providers of service by varying the cost share depending on the “tier” of hospital they visit.
Low hepatitis B knowledge among pe- rinatal healthcare providers serving county with nation’s highest rate of births to mothers chronically infected with hepatitis B buy cheap super p-force 160 mg line impotence forum. The estimated direct medical cost of sexually transmitted diseases among American youth generic 160 mg super p-force with amex erectile dysfunction treatment atlanta, 2000 cheap super p-force 160 mg erectile dysfunction normal age. Chronic hepatitis C in latinos: Natural history discount 160mg super p-force visa erectile dysfunction drugs and medicare, treatment eligibility, acceptance, and outcomes. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. Improving diabetes care in mid- west community health centers with the health disparities collaborative. Health care need and utilization: A preliminary comparison of injection drug users, other illicit drug users, and nonusers. Health care access and sociodemographic factors associated with hepatitis B testing in Vietnamese American men. Kaiser and the Health Research and Education Trust survey of employer- sponsored health benefts, - 00. The next plague: Stigmatization and discrimination re- lated to hepatitis C virus infection in Australia. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Racial differences in survival of hepatocellular car- cinoma in the United States: A population-based study. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re- incarceration and hepatitis C infection. Chronic hepatitis B reactivation following infiximab therapy in Crohn’s disease patients: Need for primary prophylaxis. Impact of four urban perinatal hepatitis B prevention programs on screening and vaccination of infants and household members. Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women. Ambulatory care sensitive hospital- izations and emergency visits: Experiences of Medicaid patients using federally qualifed health centers. Hepatitis C virus transmission among oral crack users: Viral detection on crack paraphernalia. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York city. The infuence of race and language on chronic hepatitis C virus infection management. Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: Implications for vaccination programs. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Cost-effectiveness analysis of behavioral interventions to improve vac- cination compliance in homeless adults. Evaluation of screening criteria to identify persons with hepatitis C virus infec- tion among sexually transmitted disease clinic clients: Results from the San Diego viral hepatitis integration project. Changes in injection risk behavior associated with participa- tion in the Seattle needle-exchange program. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The infuence of time and place. Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. The infuence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. A revisit of prophylactic lamivudine for chemo- therapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: A randomized trial. Reducing liver cancer disparities: A community-based hepatitis-B preven- tion program for Asian-American communities. Cost-effectiveness of screening and vaccinating Asian and Pacifc Islander adults for hepatitis B. The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings. The need for more research on language barriers in health care: A proposed research agenda. Essentials of perinatal hepatitis B prevention: A training series for coordinators and case managers—assessment and evaluation. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Managing a perinatal hepatitis B preven- tion program: A guide to life as a program coordinator. Treat- ment alternatives for chronic hepatitis B virus infection: A cost-effectiveness analysis. Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Hepatitis B virus infection and vaccination among young injection and non-injection drug users: Missed opportuni- ties to prevent infection. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Preemptive use of lamivudine reduces hepatitis B exacerbation after al- logeneic hematopoietic cell transplantation. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Productivity improvements in hepatitis C treatment: Impact on effcacy, cost, cost-effectiveness and quality of life. Why we should routinely screen Asian Ameri- can adults for hepatitis B: A cross-sectional study of Asians in California. Reactiva- tion of hepatitis B virus replication in patients receiving cytotoxic therapy. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Language concordance as a determinant of patient compliance and emer- gency room use in patients with asthma. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodefciency virus among intravenous drug users participating in a syringe/needle exchange program.
After many years the gland becomes non-functional and Investigations the patient becomes hypothyroid generic super p-force 160 mg otc erectile dysfunction hypertension drugs. Other complica- is made by a combination of clinical features and detec- tions of Graves’ disease may also be due to similar tion of thyroid autoantibodies 160 mg super p-force free shipping erectile dysfunction doctor called. Thesecomplicationsdonotresolveontreat- Management ment to reduce the overactivity of the thyroid 160mg super p-force with mastercard impotence ring. Antithyroid drugs (usually carbimazole) are given to r Some symptoms of Graves’ disease relate to apparent suppress the gland purchase super p-force 160mg without a prescription impotence 40 year old. Graves’ disease commonly enters catecholamine (noradrenaline and adrenaline) excess, remission after 12–18 months, so a trial of withdrawal for example tachycardia, tremor and sweating. Patients who are severely symptomatic roid hormones induce cardiac catecholamine recep- with hyperthyroidism also beneﬁt from β-blockers. Subtotal thyroidectomy results in normali- Primary Idiopathic/autoimmune thyroid atrophy sation of thyroid function in 70%. The patient must be made Iatrogenic: radioactive iodine, surgery, drugs euthyroid before surgery with antithyroid drugs and β- Iodine deﬁciency (common in Nepal, Bangladesh) blockers (see page 436). Inborn errors of hormone synthesis Secondary Panhypopituitarism due to pituitary adenoma Iatrogenic: pituitary ablative therapy/surgery Prognosis Tertiary Hypothalamic dysfunction (rare) Thirty to ﬁfty per cent of patients used to undergo spon- Peripheral resistance to thyroid hormone (rare) taneous remission without treatment. Hypothyroidism (myxoedema) Thyrotoxic crisis (storm) Deﬁnition Deﬁnition Hypothyroidism is a clinical syndrome resulting from a Arare syndrome of severe acute thyrotoxicosis, which deﬁciency of thyroid hormones. Pathophysiology Congenital hypothyroidism causes permanent develop- Pathophysiology mental retardation. In children it causes reversible de- Levels of thyroid-binding protein in the serum fall and layedgrowthandpuberty,anddevelopmentaldelay. This results in increased cocious puberty may occur in juveniles, due to pituitary free T3 and T4, coupled to increased sensitivity of the hypertrophy. In adults it causes decreased removal of heart and nerves due to the presence of catecholamines. The symptoms include life-threatening coma, heart fail- ure and cardiogenic shock. There is a high fever (38– Clinical features 41◦C), ﬂushing and sweating, tachycardia, often with Usually insidious onset. Central nervous creasing lethargy, forgetfulness, intolerance to cold, symptoms include agitation, restlessness, delirium and weight gain, constipation and depression (see also coma. Hypercholesterolaemia increases the incidence of tithyroid drugs and corticosteroids. Chapter 11: Thyroid axis 433 r Respiratory system: Respiration may be slow and shal- Aetiology low. Patients have detectable anti-microsomal antibody and r Gastrointestinal system: Reduced peristalsis, leading antithyroglobulin antibodies in most cases. The patient, typically a postmenopausal female, presents r Other signs include a cool rough dry skin, hair loss, with a diffuse goitre. Although most patients are euthy- puffy face and hands, a hoarse husky voice and slowed roid, thyrotoxicosis can occur and if presentation is late, reﬂexes. The thyroid is diffusely enlarged and has a ﬂeshy white cut surface due to lymphocytic inﬁltration, which is seen Investigations on microscopy around the destroyed follicles. Thyroid autoantibodies are High titres of circulating antithyroid antibodies, associ- present in patients with autoimmune disease. Large goitres require subtotal thyroidectomy if causing com- Management pression of local structures such as the oesophagus or Thyroxine replacement starting with a low dose is re- trachea. Treatment of elderly patients should be recurrent laryngeal nerves or parathyroids. Post-surgery undertaken with care, as any subclinical ischaemic heart or following signiﬁcant thyroid destruction patients be- disease may be unmasked. Thyroxine dosing is titrated come hypothyroid requiring treatment with thyroxine according to thyroid function tests. Hashimoto’s disease (autoimmune Myxoedema coma thyroiditis) Deﬁnition Deﬁnition This is the end-stage of untreated hypothyroidism, lead- Organ-speciﬁc autoimmune disease causing thyroiditis ing to progressive weakness, hypothermia, respiratory and later hypothyroidism. Myxoedema coma may be precipitated by inter- Malignant tumours of the thyroid current illness or disorder, such as heart failure, perhaps Papillary adenocarcinoma following a myocardial infarction, stroke, pneumonia; iatrogenic causes include water overload and sedative or Deﬁnition opiate drugs. A slow-growing, well-differentiated primary thyroid tu- mour arising from the thyroid epithelium. Pathophysiology Thyroid hormones maintain many metabolic processes Incidence/prevalence in the body. Severe and chronic lack of these hormones 50% of malignant tumours of the thyroid. F > M Clinical features Clinical features There may be a history of previous thyroid disease, Presentsasasolitaryormultifocalswellingofthethyroid. The patient appears obese with may be the only sign when there is a microscopic pri- hypothermia,yellowishdryskin,thinnedhair,puffyeyes mary. Papillary tumours spread via lymphatics within and has a slow pulse, respiration and reduced reﬂexes. Investigations Management Patients may be identiﬁed during investigation for a soli- Myxoedema coma requires admission to intensive care. Deﬁnitive diagnosis r Respiratory failure requires support and may necessi- is by histology, although cytology from ﬁne needle aspi- tate ventilation. Management r Corticosteroids must be given if adrenal insufﬁciency Total thyroidectomy with excision of involved neck is present. Radioactive iodine therapy may Chapter 11: Thyroid axis 435 be used prophylactically or as treatment for metastases. A postoperative radioisotope scan of the Prognosis skeleton and neck detects metastases as ‘hot spots’, and Tenyear survival rates of almost 90%. Plasma thyroglob- Follicular adenocarcinoma ulin levels can be monitored for recurrence. Deﬁnition Aprimary malignancy of the thyroid gland arising from Medullary carcinoma the thyroid epithelium. Deﬁnition Incidence/prevalence Tumour of the thyroid that arises from the parafollicular Approximately 20% of cases of thyroid malignancies. F > M Pathophysiology Clinical features The parafollicular cells originate from neural crest tis- Typically presents as a solitary thyroid nodule in middle- sue during embryonic life, but merge with the embry- aged patients. Parafollicular cells normally secrete calcitonin, a Investigations polypeptide, in response to small increases in calcium. Patients are investigated as for a solitary thyroid nodule The tumour cells secrete calcitonin and carcinoembry- (see page 430). Twenty per cent lymph nodes are palpable in about half of cases, but of patients have metastases in the lungs, bone or liver. Resembles a benign solitary thyroid nodule, a round encapsulated mass, but less colloid and more solid in Microscopy appearance. Histology reveals invasion of the capsule, The tumour is composed of sheets of small cells blood vessels and surrounding gland. Investigations Thyroidectomy Calcitonin levels are raised, although serum calcium lev- Hyperthyroid patients must be made euthyroid before els are normal. Calcitonin is also used for follow-up and thyroid surgery using antithyroid drugs and β-blockers for screening of relatives. The thyroid is exposed via a transverse skin-crease Management incision above the sternal notch. The lobes of the thy- Total thyroidectomy and dissection of lymph nodes in roid are supplied by the superior and inferior artery, the central neck compartment. These are dissected out, ligated and divided removing the desired amount of thyroid tissue. Surrounding struc- Anaplastic carcinoma tures that require identiﬁcation and protection include Deﬁnition the parathyroid glands and the recurrent laryngeal This is a highly malignant tumour of the thyroid.
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www super p-force 160mg erectile dysfunction natural herbs. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www super p-force 160mg line impotence vacuum device. In addition order 160mg super p-force overnight delivery injections for erectile dysfunction after prostate surgery, viral hepatitis education and training activities are administered by the Bureau of Health Professions cheap 160mg super p-force with mastercard erectile dysfunction causes std. Medicare covers people 65 years old or older, people under 65 years old who have specifed disabilities, and people who have end-stage renal disease. Medicaid is a state-administered program available to low-income individuals and fami- lies who ft into an eligibility group that is recognized by federal and state law. Eligibility for Medicaid and coverage for viral hepatitis services vary from state to state. The total funding level is about $5 million per year, and the average award is $90,000. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. About 78% of the plans include hepatitis B vaccinations whether or not other hepatitis B pre- vention services are included. The medical management component is included in the smallest percentage of plans (62. Overall, the coordinator survey revealed that over 40% of juris- dictions do not have plans; of the states that do have plans, only half have all the components, and only 20. The primary barrier to plan implementation was fnancial constraints on overall funding and staffng (96. Most of them focus on advocacy efforts, such as raising public awareness about viral hepatitis and encour- aging people, especially in high-risk populations, to be vaccinated for hepatitis B, to undergo risk-factor screening for hepatitis B and hepatitis C, and to determine whether laboratory testing and medical management are needed. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. The Harm Reduction Coalition is an example of an organization that develops and disseminates hepatitis C information among illicit-drug users (Harm Reduction Coalition, 2009). Existing efforts at interagency information exchange, intermittent meetings to share plans and results, and joint administration of funds for some grants are not suffcient for the scale of the health burden presented by hepatitis B and hepatitis C. Community outreach and immunization for pri- mary prevention are discussed in depth in Chapters 3 and 4, respectively. Identifcation of infected persons, harm reduction, and medical manage- ment are reviewed below. As discussed in Chapter 3, culturally relevant, accessible, and trusted sources of communication are required to increase awareness and promote use of appropriate services. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Risk factors include being born in a country where the disease is prevalent, and behavior such as illicit-drug use and having multiple sexual partners. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Providers should review patients’ backgrounds (for example, country of birth) and discuss relevant behaviors to determine what services they need. Figure 5-1 illustrates the pathway of services and care for people de- pending on their risk factors identifed. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Risk-factor screening has been tested by using question- Copyright © National Academy of Sciences. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. It has been found to correlate with infection status and is an effective mechanism for identifying candidates for testing (Armstrong et al. Researchers who were evaluating hepatitis C incidence along the Texas–Mexico bor- der found tattooing to be an independent risk factor for infection in their majority-Hispanic population (Hand and Vasquez, 2005). Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. As effective antiretroviral therapies emerged, recommendations for screening and testing were expanded (Myers et al. TheThe availability of rapid tests in theavailability of rapid tests in the Copyright © National Academy of Sciences. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Table 5-2 provides guidance on the interpreta- tion of hepatitis B serologic test results. Cost-effectiveness data on the use of laboratory testing in particular at- risk populations are available. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Reactivations have also been reported to occur with other types of immunosuppressives, notably anti–tumor- necrosis factor therapy for rheumatoid arthritis and infammatory bowel disease (Esteve et al. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. Research to develop a vaccine for hepatitis C continues although it is unlikely that a vaccine will be developed and licensed in the near future. Given the com- plexity of the issues surrounding vaccination of children and adults, this report devotes a separate chapter (Chapter 4) to immunization. Support for abstinence is an element of harm reduction but is not a requirement for participation in harm-reduction programs. Harm reduction focuses on providing information about safer practices (for ex- ample, how to inject without exposing oneself to contaminated blood), providing materials for engaging in safer practices (such as needle syringes and condoms), and offering hepatitis B vaccination. Because harm reduc- tion does not condemn illicit-drug use and instead seeks practical solutions to mitigate its harmful consequences, these programs can be controversial (Des Jarlais et al. The guidelines are updated regularly to refect advances in care and should be referred to as the basis of appropri- ate medical management. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www. In addition, any pa- tient who has stigmata of liver disease—ascites, enlarged spleen, jaundice, or encephalopathy—or a platelet count below 100,000 (which is a sign of possible splenomegaly) should be referred immediately to a specialist. The primary care provider should take a his- tory and perform a physical examination with emphasis on symptoms and signs of liver disease. Patients found to have signs or symptoms of liver disease or a low platelet count (below 100,000) should be referred to a specialist who has experience in managing persons with advanced hepatitis C. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C http://www.